

Experience the Difference.
EXPERIENCE AXONICS.

REVOLUTIONISING Sacral Neuromodulation Therapy

Axonics
.....SNM.....



Revolutionising Sacral Neuromodulation Therapy

In 2018, Axonics introduced long-awaited innovation in Sacral Neuromodulation therapy, including a miniaturised and long-lived neurostimulator, the ability to undergo full-body MRIs, constant current stimulation, a smart programming algorithm, and easy-to-use patient accessories.

With Axonics R20, we continue to enhance the patient therapy experience by expanding MRI labeling, increasing programming options, and drastically reducing recharging needs.




System Features	AxonicsR15®	AxonicsR20®
Battery Life	15+ years	20+ years
Recharging Interval	Every 1 to 2 months*	Every 6 to 10 months*
Predictive Programming Algorithm	Yes	Yes
Patient Programs Available	One personalised program	Two personalised programs
MRI Labeling	1.5T and 3T Head Coil** 1.5T and 3T Full-Body Coil**	1.5T and 3T Head Coil** 1.5T and 3T Full-Body Coil** 1.5T and 3T Upper & Lower Extremity Coils**
Neurostimulator Size	5cc	
Neurostimulator Case	Titanium-ceramic	
Stimulation Type	Constant current	

* Recharge interval depends on therapy settings
** Under certain conditions. For more information visit www.axonics.com/MRI



Experience the Difference with Axonics R20[®]

- Recharge only every 6 to 10 months^{*}
- Proprietary titanium-ceramic design, allowing for safe and efficient charging¹
- Miniaturised device, only 5cc in volume
- 20+ year open-ended life



Intelligently Designed to Provide a Battery that Lasts and Lasts

Powered by SmartCharge, an intelligent software algorithm, the Axonics R20 System is optimised to manage and protect the neurostimulator performance while delivering 20+ years of battery life.

With SmartCharge, Axonics R20 provides:

- Protection against full discharge²
- Consistent recharging experience over the entire life of the device²
- Reliable long-lasting performance²



of initial battery capacity after

20 years


of recharging cycles^{*2}

^{*} Assumes nominal stimulation parameters and a full charge-discharge cycle every 6 months. 40 cycles correspond to 20 years of recharging cycles if charging every 6 months.

Enabling Easy Therapy Management

Patient Remote Control

- Pocket-sized, no recharging required
- Simplifies the therapy experience by eliminating the need for any external antennas or communicators
- Easily adjusts therapy levels for both trial and permanent therapies
- Checks if system is ready for full-body MRI without requiring a hospital visit




Offers your Patients Access to MRI

- The Axonics R20® System is MRI conditionally safe for 1.5T and 3T full-body, head, and upper/lower extremity MRI scans.
- Featuring **SmartMRI™ Technology**, the MRI technician can easily confirm if a patient's Axonics System is ready to undergo a full-body MRI by using the Remote Control.

Charging System

- Offers the longest recharge interval available in SNM³
- Circuitry designed to protect against full discharge and maintain battery capacity
- Simple charging experience with tones and vibrations to guide the patient



Patient **satisfaction** with **charging experience** at 2-years¹




Fuss-Free Patient and Provider Experience



Personalised Therapy for Every Patient

The Clinician Programmer features a proprietary Smart Programming algorithm, offering the following benefits:

- Simplified patient experience with two program options for easy adjustments
- Program recommendations based on intraoperative responses and lead placement, taking the “guesswork” out of programming



of patients were on one of their top two recommended programs after one year.⁴

The Smart Programming algorithm accurately predicts effective programming at implant, with minimal need for reprogramming⁴

External Trial System

- Lightweight and discreet Basic and Advanced Trial options for your patients




Interchangeable Tined Lead

- The Axonics R15® and R20® Systems use the same tined lead, providing you flexibility in managing your patient's Axonics Therapy



Clinically Proven

R15® & R20® for Urinary Control



of patients had **≥50%** reduction in UUI symptoms at 2-years post-implant¹




82%

of treatment responders had **≥75%** reduction in urgency leaks¹



37%

of treatment responders were dry¹



of patients treated with Axonics Therapy were satisfied at 2-years¹


R15® for Bowel Control



87%

of patients experienced **≥50%** reduction in FI symptoms⁵

The ARTISTRY study shows high rates of successful FI treatment.⁴



The **ARTISAN-SNM Clinical Study** showed <2% of patients had discomfort at the INS site, with no surgical intervention at 2-years and no serious device-related adverse events.¹

At 2-Years:

<1%

rate of lead migration was observed¹

<2%

rate of open impedances¹

<2%

of patients reported discomfort at the INS site, with no surgical revisions needed¹

Celebrating over 7 years of symptom relief.

"It's been an absolute life-changer for me and my family. I can't imagine life without Axonics."

Wendy G. | 45 years old

Results and experiences may vary and are unique to each patient.



Long-Lasting SNM Therapy that is Not Dependent on Therapy Settings

When compared to InterStim X®, Axonics R20 offers significant advancements to the therapy.


The 20+ year open-ended life of the Axonics R20 System provides the benefit of a long-lasting therapy, even for patients with high energy stimulation settings.

Expected Battery Longevity Based on Stimulation Settings⁶

	0.10 mA	0.50 mA	1.00 mA	2.00 mA	5.00 mA
AxonicsR20®	20+ yrs	20+ yrs	20+ yrs	20+ yrs	20+ yrs
InterStim X® ⁶	16.1 yrs	12.3 yrs	10.2 yrs	7.6 yrs	2.6 yrs

The Axonics R20 System is designed to minimise energy consumption to help maximise the recharge interval for your patients. The result is an unmatched recharge interval that allows patients the freedom to **recharge 1 to 2 times a year vs 19 times** with InterStim® Micro.³

Recharge Episodes Per Year⁷



AxonicsR20®
The therapy experience
your patients deserve.





To learn more, contact your local Axonics representative or scan below.



www.axonics.com/r20eu

References:

1. Pezzella A, McCrery R, Lane F, et al. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system. *Neurol Urodyn*. 2021
2. Company data on file
3. Charging manual for the Axonics R20 System, Company data on file (charging interval), InterStim® System eligibility, battery longevity, specifications 2021-11-01 (M988757A016 Rev B). At therapy settings for both devices: 1.0 mA, 1200 Ohms, 14 Hz, 210 µS.
4. ARTISTRY Registry data on file. October 2023
5. Jottard K, et al. International Neuromodulation Society 2021.
6. Battery life from InterStim X® System specifications Manual M988757A016 Rev B
7. Company Data on File 110-0022-004rA

IMPORTANT SAFETY INFORMATION

Indications: The Axonics R20 System for urinary control is indicated for the treatment of the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

The Axonics R15 System for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence (leakage) and significant symptoms of urgency-frequency, either alone or in combination, in patients who have failed or could not tolerate more conservative treatments. The Axonics R15 System for bowel control is indicated for the treatment of chronic faecal incontinence in patients who have failed or are not candidates for more conservative treatments.

Contraindications: The Axonics SNM System is contraindicated for patients who have not demonstrated an appropriate response to test stimulation or patients who are unable to operate the Axonics SNM System.

Warnings: Implantation and use of the Axonics System incurs risk beyond those normally associated with surgery, some of which may necessitate surgical intervention. These risks include but are not limited to adverse change in voiding, infection, pain, or irritation at the implant site, lead or device migration, electrical shock, change in sensation or magnitude of stimulation which has been described as uncomfortable (jolting or shocking) by some patients, and heating or burns at the device site.

Precautions: The safety and effectiveness of the Axonics R15 System has not been established for use in women who are pregnant or in delivery; for pediatric patients (under the age of 18 years for faecal incontinence and under the age of 16 years for overactive bladder and urinary retention); for patients with neurological disease origins, such as multiple sclerosis or diabetes; or for bilateral stimulation.

The safety and effectiveness of the Axonics R20 System has not been established for use in women who are pregnant or in delivery; for pediatric patients under the age of 16 years; for patients with neurological disease origins, such as multiple sclerosis or diabetes; or for bilateral stimulation.

For a complete listing of indications, contraindications, warnings and precautions, go to www.axonics.com/isi

For Summary of Safety and Clinical Performance (SSCP), refer to <https://ec.europa.eu/tools/eudamed/#/screen/home>.

Adverse Event Reporting: In case of any serious incident related to the product, please report to Axonics (+877-929-6642 or customersupport@axonics.com) as well as the competent authority of your state.

© 2021-2024 Axonics, Inc. All rights reserved. This material contains registered trademarks, trade names, and brand names of Axonics, Inc. InterStim X and InterStim are registered trademarks of Medtronic, Inc. All trademarks are the property of their respective owners. 110-0368-101rC 03/2024



Emergo Europe B.V. Westervoortsedijk 60
6827 AT Arnhem The Netherlands

R_X ONLY

CE
2797



Stay Connected. #Axonics

 Axonics

www.axonics.com